Evista Related Published Studies
Well-designed clinical trials related to Evista (Raloxifene)
The effect of raloxifene treatment in postmenopausal women with CKD. [2008.07]
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. [2008.06.18]
Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women >/= 70 years: Study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial. [2008.06.05]
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. [2008.05]
The Effect of Raloxifene Treatment in Postmenopausal Women with CKD. [2008.04.09]
Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. [2008.04]
Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. [2008.04]
Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis. [2008.03]
Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. [2008.03]
Comparison of effects of alendronate and raloxifene on lumbar bone mineral density, bone turnover, and lipid metabolism in elderly women with osteoporosis. [2008.02.29]
Role of raloxifene on platelet metabolism and plasma lipids. [2008.02]
Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. [2008.01.20]
Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial. [2008.01]
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. [2008.01]
Raloxifene, soy phytoestrogens and endothelial function in postmenopausal women. [2007.12]
Cognitive effects of short-term use of raloxifene: a randomized clinical trial. [2007.11]
A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women. [2007.11]
Rapid endometrial preparation for hysteroscopic surgery with oral desogestrel plus vaginal raloxifene: a prospective, randomized pilot study. [2007.09]
Effect of raloxifene treatment on osteocyte apoptosis in postmenopausal women. [2007.09]
Raloxifene slows down the progression of intima-media thickness in postmenopausal women. [2007.09]
Effect of raloxifene-a selective oestrogen receptor modulator-on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial. [2007.08]
The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women. [2007.08]
Raloxifene improves the ovariectomy-induced impairment in endothelium-dependent vasodilation. [2007.07]
Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. [2007.07]
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. [2007.07]
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. [2007.06]
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. [2007.05]
Effect of raloxifene-a selective oestrogen receptor modulator-on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial. [2007.04.19]
Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study. [2007.01]
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. [2007]
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. [2007]
Effects of intranasal 17beta-estradiol and raloxifene on lipid profile and fibrinogen in hypercholesterolemic postmenopausal women: a randomized, placebo-controlled clinical trial. [2006.12]
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. [2006.10.20]
Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. [2006.07.13]
Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene. [2006.07]
Effects of raloxifene on lipid and lipoprotein levels in postmenopausal osteoporotic women with and without hypertriglyceridemia. [2006.07]
Effects of raloxifene on sex steroid hormones and C-telopeptide in postmenopausal women with primary breast cancer. [2006.07]
Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. [2006.07]
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. [2006.06.21]
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. [2006.06.21]
Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. [2006.05]
The effect of raloxifene on cardiac autonomic regulation in osteoporotic women. [2006.05]
The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis. [2006.03]
The effect of raloxifene and tibolone on the uterine blood flow and endometrial thickness: a transvaginal Doppler study. [2006.02.20]
Effects of estrogen, raloxifene, and hormone replacement therapy on serum C-reactive protein and homocysteine levels. [2006.02.20]
Anti-vertebral fracture efficacy of raloxifene: a meta-analysis. [2006.02]
[Raloxifene in postmenopausal women] [2006.02]
Raloxifene reduces fractures in postmenopausal women with osteoporosis. [2006.02]
Effects of raloxifene on normal breast tissue from premenopausal women. [2006.01]
Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. [2006]
Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial. [2006]
The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial. [2005.12]
Effect of raloxifene on aortic elasticity in healthy postmenopausal women. [2005.12]
Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. [2005.12]
Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? [2005.12]
Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial. [2005.11]
[Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women] [2005.10]
A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. [2005.09.16]
Safety assessment of raloxifene over eight years in a clinical trial setting. [2005.09]
Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. [2005.09]
Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment. [2005.09]
Vitamin D insufficiency does not affect bone mineral density response to raloxifene. [2005.08]
Effects of raloxifene, hormone therapy, and soy isoflavone on serum high-sensitive C-reactive protein in postmenopausal women. [2005.08]
Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. [2005.07.16]
Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women. [2005.07]
Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene. [2005.07]
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. [2005.07]
Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia. [2005.07]
Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-deficient women. [2005.07]
Raloxifene and colorectal cancer. [2005.05]
Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women. [2005.04.11]
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. [2005.04]
Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. [2005.03.14]
Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. [2005.03]
Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. [2005.03]
Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. [2005.03]
Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. [2005.03]
Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. [2005.01]
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. [2005.01]
Protection of bone mass by estrogens and raloxifene during exercise-induced weight Loss. [2005.01]
Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature. [2005]
Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. [2005]
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. [2004.12.01]
Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. [2004.12.01]
Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. [2004.12]
Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. [2004.11]
Effect of raloxifene on activated protein C (APC) resistance in postmenopausal women and on APC resistance and homocysteine levels in elderly men: two randomized placebo-controlled studies. [2004.10]
Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy. [2004.10]
Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. [2004.10]
Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women. [2004.09]
Raloxifene and hormone replacement therapy increase arachidonic acid and docosahexaenoic acid levels in postmenopausal women. [2004.09]
Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. [2004.09]
Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. [2004.08]
Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. [2004.08]
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. [2004.08]
Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate. [2004.07]
Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial. [2004.07]
Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. [2004.07]
Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. [2004.07]
Comparative vascular effects of hormone replacement therapy and raloxifene in women at increased cardiovascular risk. [2004.06]
The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. [2004.06]
|
